Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (66)

View All

Latest Posts

About This Stock More About This Stock
5 Drug/Biotech Stocks Likely To Beat Q3 Earnings Estimates
Article By: Zacks Investment Research
Sunday, October 28, 2018 2:00 PM EST
There are a number of drug/biotech companies poised to surpass third-quarter estimates. However, given the large number of drug/biotech firms, the task of selecting stocks with possibilities to beat could appear quite daunting.
In this article: REGN, AGN, AMGN, ALNY, AMAG
Read
August 11, 20018 Week In Review: How Trump's Policies Moved Stocks
Article By: The Fly
Saturday, August 11, 2018 9:37 PM EST
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap.
In this article: L, AA, AKS, BA, CLF, JNJ, NUE, X, DDAIF, RHHBY, REGN, AAPL, AMGN, CENX, STLD
Read
Stocks For You To Swing-Trade: REGN, CMA, SCHW
Article By: Ryan Mallory
Friday, August 3, 2018 6:04 AM EST
Take a look at three trading ideas to prep you for the next trading session.
In this article: CMA, SCHW, REGN
Read
Q2 Earnings Update: Bluebird Bio (BLUE) And Regeneron (REGN)
Article By: Rod Raynovich
Thursday, August 2, 2018 11:09 PM EST
Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. Bluebird Bio (BLUE) was up 0.79% to $156.60 despite losses and lagging revenue.
In this article: BLUE, REGN
Read
Biotechnology Stocks Preparing A New Bullish Trend
Article By: Taki Tsaklanos
Sunday, July 8, 2018 11:26 AM EST
Biotechnology stocks look bullish, and even more bullish than ever in the last three years.
In this article: IBB, ILMN, REGN, BIIB, CELG, XBI, ARRY, FOLD, SGMO, XLRN
Read
All Posts

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!

$REGN

Comments Status Updates
Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner • 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments